Explode / Shutterstock.com
20 November 2020AmericasRory O'Neill
Medicure and Nexus agree Aggrastat generic licence
US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
19 June 2017 The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.
Americas
20 February 2017 Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.
Americas
19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Editor's picks
Editor's picks
Americas
19 June 2017 The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.
Americas
20 February 2017 Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.
Americas
19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Americas
19 June 2017 The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.
Americas
20 February 2017 Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.
Americas
19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.